None listed
Conditions
Brief summary
Fenofibrate is a drug largely used in patients with type 2 diabetes and mixed dyslipidemia due to its effects of reducing triglycerides concentration and enhancing HDL cholesterol levels. Also there are a lot of evidences regarding the pleiotropic effects of fenofibrate such as: decrease in systemic inflammation and monocyte cytokine release, improvement in insulin sensitivity and hemostasis, important antioxidant, antithrombotic and antiplatelet activities. In light of the foregoing data, the main purpose of this study was to investigate the role of fenofibrate on plasma MPO concentrations in patients with type 2 diabetes
Interventions
to investigate the role of fenofibrate on plasma myeloperoxidase concentrations in patients with type 2 diabetes.
Starting from visit 1, each subject received daily treatment with oral tablets of fenofibrate 160 mg once daily for 8 weeks.
Sponsors
Nita Cristina
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
patients with type 2 diabetes treated with metformin monotherapy without previous diagnosis of dyslipidemia and/or use of lipid-lowering medication
Exclusion criteria
type 1 diabetes mellitus treatment with other hypoglycaemic drugs in the past 3 months, recent acute cardiovascular event within 3 months, uncontrolled endocrine or metabolic diseases chronic kidney disease persistent elevation of alanine aminotransferase, aspartate aminotransferase, history of alcohol abuse, previous treatment with any lipid-lowering drugs, changes in hypoglycaemic or antihypertensive treatment during the last 3 months
Outcome results
None listed